With trials on a pandemic pause, Winston & Strawn’s gross revenue declined by roughly 3% to $981.2 million last year. But profits were bolstered by reduced expenses, said firm chairman Tom Fitzgerald, and profits per equity partner increased by 4.6%, to $2.42 million.
Winston had “almost double digits” in terms of the number of scheduled trials postponed in 2020 because of COVID-19, Fitzgerald said in an interview, but he noted that a silver lining was the ability to cut travel and other expenses while maintaining productivity in a remote environment.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]